'Don't eat me' cancer drug developer asks investors to chow down on $115 million IPO

The Menlo Park-based company's IPO filing is yet another example of how companies aimed at helping the immune system detect and destroy cancers are hot properties on Wall Street.

Source: bizjournals.com Health Care:Physician Practices headlines - June 4, 2018 Category: American Health Authors: Ron Leuty Source Type: news